The Phenomenon of Multidrug Resistance in GlioblastomasAlexander N. Chernov, О. В. Шамова, Ilaria Meloni et al.|Hematology/Oncology and Stem Cell Therapy|2021Cited by 27
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma CellsAlexander N. Chernov, О. В. Шамова, Evgeniy Victorovich Fedorov et al.|Molecules|2022Cited by 16
In Vitro Evaluation of the Cytotoxic Effect of Streptococcus pyogenes Strains, Protegrin PG-1, Cathelicidin LL-37, Nerve Growth Factor and Chemotherapy on the C6 Glioma Cell LineAlexander N. Chernov, А. Н. Суворов, Anna Tsapieva et al.|Molecules|2022Cited by 15
Nerve Growth Factor, Antimicrobial Peptides and Chemotherapy: Glioblastoma Combination Therapy to Improve Their EfficacyAlexander N. Chernov, О. В. Шамова, I. V. Kudryavtsev et al.|Biomedicines|2023Cited by 7
Related expression of TRKA and P75 receptors and the changing copy number of<i>MYC</i>-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomideAlexander N. Chernov, О. В. Шамова, Diana Alaverdian et al.|Drug Metabolism and Personalized Therapy|2020Cited by 1